Ionis Pharmaceuticals Company Insiders
| IONS Stock | USD 79.67 0.56 0.71% |
Ionis Pharmaceuticals employs about 1.1 K people. The company is managed by 25 executives with a total tenure of roughly 101 years, averaging almost 4.0 years of service per executive, having 42.76 employees per reported executive. Breaking down Ionis Pharmaceuticals' management performance can provide insight into the firm performance.
| Stanley Crooke Chairman Chairman of the Board and Presidentident, CEO |
| Frank Bennett President Senior Vice President - Antisense Research |
Ionis Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.0568) % which means that it has lost $0.0568 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4004) %, meaning that it created substantial loss on money invested by shareholders. Ionis Pharmaceuticals' management efficiency ratios could be used to measure how well Ionis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The majority of Ionis Pharmaceuticals outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Ionis Pharmaceuticals to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Ionis Pharmaceuticals. Please pay attention to any change in the institutional holdings of Ionis Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.
Some institutional investors establish a significant position in stocks such as Ionis Pharmaceuticals in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Ionis Pharmaceuticals, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Ionis Pharmaceuticals Workforce Comparison
Ionis Pharmaceuticals is rated fifth overall in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 17,043. Ionis Pharmaceuticals holds roughly 1,069 in number of employees claiming about 6% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.27) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.02) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.02. Ionis Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ionis Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ionis Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Ionis Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ionis Pharmaceuticals Notable Stakeholders
An Ionis Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Ionis Pharmaceuticals often face trade-offs trying to please all of them. Ionis Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Ionis Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Stanley Crooke | Chairman of the Board and Presidentident, CEO | Profile | |
| Wade Walke | Vice President - Corporate Communications | Profile | |
| Frank Bennett | Senior Vice President - Antisense Research | Profile | |
| MA MBA | Executive CFO | Profile | |
| Elizabeth Hougen | CFO and Sr. VP of Fin. | Profile | |
| Brett Monia | Sr. VP of Drug Discovery and Corporate Devel. | Profile | |
| Sanjay MD | Chief VP | Profile | |
| Eugene MD | Chief VP | Profile | |
| Sujit Basu | VP Development | Profile | |
| Patrick Esq | Chief VP | Profile | |
| Hayley Soffer | Vice Communications | Profile | |
| Hala Mirza | Senior Advocacy | Profile | |
| Richard Geary | Executive Officer | Profile | |
| Onaiza CadoretManier | Chief VP | Profile | |
| Tracy JD | Senior Officer | Profile | |
| Dr BSc | Executive Officer | Profile | |
| Kyle Jenne | Executive Officer | Profile | |
| Eric Swayze | Executive Research | Profile | |
| JD Esq | Strategic Director | Profile | |
| Joel Edwards | VP Operations | Profile | |
| Shannon Devers | Executive Officer | Profile | |
| Holly Kordasiewicz | Senior Neurology | Profile | |
| Darren Gonzales | Chief VP | Profile | |
| Matt JD | Senior Affairs | Profile | |
| Rachel Carnes | Senior Strategy | Profile |
About Ionis Pharmaceuticals Management Performance
The success or failure of an entity such as Ionis Pharmaceuticals often depends on how effective the management is. Ionis Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Ionis management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Ionis management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California. Ionis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 660 people.
Please note, the imprecision that can be found in Ionis Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Ionis Pharmaceuticals. Check Ionis Pharmaceuticals' Beneish M Score to see the likelihood of Ionis Pharmaceuticals' management manipulating its earnings.
Ionis Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Ionis Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Ionis Pharmaceuticals within its industry.Ionis Pharmaceuticals Manpower Efficiency
Return on Ionis Pharmaceuticals Manpower
| Revenue Per Employee | 659.6K | |
| Revenue Per Executive | 28.2M | |
| Net Loss Per Employee | 424.6K | |
| Net Loss Per Executive | 18.2M | |
| Working Capital Per Employee | 2.2M | |
| Working Capital Per Executive | 92.4M |
Additional Tools for Ionis Stock Analysis
When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.